参考文献/References:
[1] Roth GA,Mensah GA,Johnson CO,et al. Global burden of cardiovascular diseases and risk factors,1990-2019:update from the GBD 2019 study[J]. J Am Coll Cardiol,2020,76(25):2982-3021.
[2] Virani SS,Alonso A,Aparicio HJ,et al. Heart disease and stroke statistics—2021 update:a report from the American Heart Association[J]. Circulation,2021,143(8):e254-e743.
[3] Ambrosy AP,Fonarow GC,Butler J,et al. The global health and economic burden of hospitalizations for heart failure:lessons learned from hospitalized heart failure registries[J]. J Am Coll Cardiol,2014,63(12):1123-1133.
[4] McDonagh TA,Metra M,Adamo M,et al. Corrigendum to:2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC) With the special contribution of the Heart Failure Association(HFA) of the ESC[J]. Eur Heart J,2021,42(48):4901.
[5] Miller CL,Oikawa M,Cai Y,et al. Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy[J]. Circ Res,2009,105(10):956-964.
[6] Vandeput F,Wolda SL,Krall J,et al. Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes[J]. J Biol Chem,2007,282(45):32749-32757.
[7] Hashimoto T,Kim GE,Tunin RS,et al. Acute enhancement of cardiac function by phosphodiesterase type 1 inhibition[J]. Circulation,2018,138(18):1974-1987.
[8] Schermuly RT,Pullamsetti SS,Kwapiszewska G,et al. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension:target for reverse-remodeling therapy[J]. Circulation,2007,115(17):2331-2339.
[9] Lugnier C. PDE inhibitors:a new approach to treat metabolic syndrome?[J]. Curr Opin Pharmacol,2011,11(6):698-706.
[10] Zhang H,Pan B,Wu P,et al. PDE1 inhibition facilitates proteasomal degradation of misfolded proteins and protects against cardiac proteinopathy[J]. Sci Adv,2019,5(5):eaaw5870.
[11] Knight WE,Chen S,Zhang Y,et al. PDE1C deficiency antagonizes pathological cardiac remodeling and dysfunction[J]. Proc Natl Acad Sci U S A,2016,113(45):E7116-E7125.
[12] Giachini FR,Lima VV,Carneiro FS,et al. Decreased cGMP level contributes to increased contraction in arteries from hypertensive rats:role of phosphodiesterase 1[J]. Hypertension,2011,57(3):655-663.
[13] Yu J,Wolda SL,Frazier AL,et al. Identification and characterisation of a human calmodulin-stimulated phosphodiesterase PDE1B1[J]. Cell Signal,1997,9(7):519-529.
[14] Miller CL,Cai Y,Oikawa M,et al. Cyclic nucleotide phosphodiesterase 1A:a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart[J]. Basic Res Cardiol,2011,106(6):1023-1039.
[15] Wang X,Yamada S,LaRiviere WB,et al. Generation and phenotypic characterization of Pde1a mutant mice[J]. PLoS One,2017,12(7):e0181087.
[16] Nagel DJ,Aizawa T,Jeon KI,et al. Role of nuclear Ca2+/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival[J]. Circ Res,2006,98(6):777-784.
[17] Bautista Ni?o PK,Durik M,Danser AH,et al. Phosphodiesterase 1 regulation is a key mechanism in vascular aging[J]. Clin Sci(Lond),2015,129(12):1061-1075.
[18] Snyder GL,Prickaerts J,Wadenberg ML,et al. Preclinical profile of ITI-214,an inhibitor of phosphodiesterase 1,for enhancement of memory performance in rats[J]. Psychopharmacology(Berl),2016,233(17):3113-3124.
[19] Muller GK,Song J,Jani V,et al. PDE1 inhibition modulates Cav1.2 channel to stimulate cardiomyocyte contraction[J]. Circ Res,2021,129(9):872-886.
[20] Yang HY,Lin FZ,Yang HW,et al. The effect of Sirt1 deficiency on Ca2+ and Na+ regulation in mouse ventricular myocytes[J]. J Cell Mol Med,2020,24(12):6762-6772.
[21] Yang HW,Lin CY,Lin FZ,et al. Phosphodiesterase-1 inhibitor modulates Ca2+ regulation in sirtuin 1-deficient mouse cardiomyocytes[J]. Eur J Pharmacol,2021,910:174498.
[22] Yugo D,Chen YC,Lin YK,et al. Effects of phosphodiesterase-1 inhibitor on pulmonary vein electrophysiology and arrhythmogenesis[J]. Eur J Clin Invest,2021,51(9):e13585.
[23] Golshiri K,Ataei Ataabadi E,Rubio-Beltran E,et al. Selective PDE1 inhibition ameliorates vascular function,reduces inflammatory response,and lowers blood pressure in ageing animals[J]. J Pharmacol Exp Ther,2021,378(2):173-183.
[24] Gilotra NA,DeVore AD,Povsic TJ,et al. Acute hemodynamic effects and tolerability of phosphodiesterase-1 inhibition with ITI-214 in human systolic heart failure[J]. Circ Heart Fail,2021,14(9):e0008236.
[25] Fleming GA,Murray KT,Yu C,et al. Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery[J]. Circulation,2008,118(16):1619-1625.
[26] Lin YK,Chen YC,Chen YA,et al. Levosimendan differentially modulates electrophysiological activities of sinoatrial nodes,pulmonary veins,and the left and right atria[J]. J Cardiovasc Electrophysiol,2018,29(8):1150-1158.